Form 10-Q NANOVIRICIDES, INC. For: Dec 31
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq hits intraday record high on Alphabet boost, Mideast negotiation hopes
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Oil falls to two-week low as Gulf supply outlook improves
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
NanoViricides (NNVC) Reports Q2 Loss of $0.04/Share
February 25, 2015 9:21 AM ESTNanoViricides (AMEX: NNVC) reported Q2 EPS of ($0.04), versus ($0.03) reported last year. Revenue for the quarter came in at $1.82 million, versus $1.75 million reported last year.
The Company estimates that it now has approximately $36.4 Million (M) of current assets plus restricted cash (cash, cash equivalents, collateral advance, prepaid expenses, and security deposits) as of December 31, 2014, the end of the reporting quarter. The Company's operating expenditure during this quarter was approximately $1.9M. Shareholder equity stood at approximately $30.5M for the quarter.
The Company reports that all of its drug development programs are progressing... More
